Is Aclarion, Inc. (ACONW) Halal?

NASDAQ United States N/A
? INSUFFICIENT DATA
Confidence: 0/100
Aclarion, Inc. (ACONW) has insufficient data for a complete Shariah compliance screening. This may be due to missing financial statements or incomplete market data.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI N/A N/A N/A N/A ? INSUFFICIENT DATA
DJIM N/A N/A N/A N/A ? INSUFFICIENT DATA
MSCI 0.0%
/ 33%
21.4%
/ 33%
0.9%
/ 33%
0.7%
/ 5%
✓ HALAL
S&P N/A N/A N/A N/A ? INSUFFICIENT DATA
FTSE 0.0%
/ 33%
21.4%
/ 33%
0.9%
/ 50%
0.7%
/ 5%
✓ HALAL

Financial Highlights

EPS
$-6.58
P/B Ratio
0.0
Revenue
$45,724
Growth: 31.5%
Beta
1.4
High volatility
Current Ratio
17.0

Profitability

Gross Margin -7.8%
Operating Margin -9666.2%
Net Margin 0.0%
Return on Equity (ROE) -97.7%
Return on Assets (ROA) -52.4%

Cash Flow & Balance Sheet

Operating Cash Flow-$5M
Free Cash Flow-$6M
Current Ratio17.0
Total Assets$2M

Price & Trading

Last Close$0.03
Beta1.4

About Aclarion, Inc. (ACONW)

CEO
Mr. Brent Ness
Employees
5
Country
United States
Exchange
NASDAQ
Currency
USD

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Related Halal Stocks in

Frequently Asked Questions

Is Aclarion, Inc. (ACONW) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aclarion, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Aclarion, Inc.'s debt ratio?

Aclarion, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are Aclarion, Inc.'s key financial metrics?

Aclarion, Inc. has a market capitalization of N/A, and revenue of $45,724. Return on equity stands at -97.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.